Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?

Future oncology (London, England) - 1 Apr 2018

Rossi Sabrina, Di Noia Vincenzo, Tonetti Laura, Strippoli Antonia, Basso Michele, Schinzari Giovanni, Cassano Alessandra, Leone Antonio, Barone Carlo, D'Argento Ettore

Abstract excerpt

AIM: To evaluate gefitinib outcomes in EGFR-mutated non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations, according to their sarcopenia status. PATIENTS & METHODS: We retrospectively evaluated 33 patients with advanced NSCLC and EGFR mutations (exon 19 or 21), dividing them into sarcopenic patients, with low skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men, and nonsarcopenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cachexia
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Gefitinib

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Sarcopenia

Share to Survival Analysis

Source

Identifiers

PMID: 29528255
DOI: 10.2217/fon-2017-0499

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?PMID 29528255Read ↗

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.Semantic proximity Read ↗

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib.Semantic proximity Read ↗

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Could Sarcopenia be Related to Chemotherapy in Gastrointestinal Cancer? A Cross-Sectional Study Including Comprehensive Geriatric AssessmentSemantic proximity Read ↗

Independent and joint association of sarcopenia and frailty with mortality in older patients with gastrointestinal cancer: A cohort study with prospective data collectionSemantic proximity Read ↗

The Impact of Sarcopenia on Overall Survival in Patients with Pan-RAS Wild-type Colorectal Liver Metastasis Receiving HepatectomySemantic proximity Read ↗

Development and Validation of a Clinically Useful Nomogram for Predicting Sarcopenia in Bone Tumor PatientsSemantic proximity Read ↗

Prevalence and associated factors of sarcopenia in cervical cancer patients undergoing chemotherapySemantic proximity Read ↗

The Predictive Value of the EWGSOP Definition of Sarcopenia: Results From the InCHIANTI Study.Semantic proximity Read ↗

Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.Semantic proximity Read ↗

Role of cachexia in advanced non-small cell lung cancer patients treated with EGFR-TKIS.Semantic proximity Read ↗

Primary tumor location is a risk factor for postoperative development of sarcopenia related to poor outcomes in patients with colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.